Drug resistance, epigenetics, and tumor cell heterogeneity.
The resistance of cancer cells to various therapeutic agents and modalities is a crucial issue in clinical oncology. A recent Cell paper highlights how changes at the chromatin level control drug sensitivity and provides insight into more effective strategies for treating cancer with combination therapies.
Hoey
Timothy
T
OncoMed Pharmaceuticals, Redwood City, CA 94063, USA. Tim.Hoey@oncomed.com
D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics*; D044127:Epigenesis, Genetic / Q000187:drug effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018740:Genetic Heterogeneity / Q000187:drug effects; D006801:Humans; D009154:Mutation / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology
D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors